Clearside Biomedical (CLSD) Reports In-Line Q3 EPS

Clearside Biomedical (NASDAQ: CLSD) reported Q3 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $260 thousand versus the consensus estimate of $410 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• JPMorgan upgrades 3M, Emerson Electric to Overweight ahead of earnings
• Freedom Broker Upgrades Morgan Stanley (MS) to Buy